Mizuho analyst Salim Syed lowered the firm’s price target on Nkarta to $20 from $25 and keeps an Outperform rating on the shares. The analyst updated the company’s model post the Q2 report. The firm decreased NKX019’s probability of success in large B-cell malignancies to 10% from 20% upon learning that the compressed dosing cohort data in B-cell lymphoma is now expected in late-2024 versus previous guidance of mid-2024.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTX:
- Nkarta reports Q2 EPS (34c), consensus (45c)
- Nkarta upgraded to Strong Buy from Outperform at Raymond James
- Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
- Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
- Nkarta’s (NKTX) Making Promising Progress in Its Clinical-Stage Journey